Studies on Characterizations, Solubility and Dissolution of Multicompoent Inclusion Complex of Domperidone using Cyclodextrin/Cyclodextrin Derivatives with Different Auxiliary Agents

Domperidone (DOMP) is an antiemetic drug, although it has low bioavailability and isn't very soluble. Our solution to these issues is the Multicompoent inclusion complex (MCIC), which we would make by combining cyclodextrin and its derivatives with various auxiliary agents/auxiliary substances (AXAs), such as citric acid, mannose, and L-arginine, among others. Compared to β-CD and H-β-CD, first tests reveal that Domperidone with M-β-Cyclodextrin produces better results. Auxiliary agents, such as citric acid, were chosen for use in multicomponent inclusion complexes. In order to determine whether method was more effective in increasing domperidone solubility, researchers compared the physical mixing method with the kneading method for preparing the multicomposite inclusion complex. Phase solubility experiments for multicompoent inclusion complexes revealed considerable improvements in complexation efficiency and stability constants. In order to characterize the multicompoent inclusion, XRD, DSC, FT-IR, and NMR were employed. When compared to the pure medication alone, the complexes demonstrated an increase in drug solubility and release through in vitro dissolving and saturation solubility experiments. This study concluded that AXAs and methyl-βcyclodextrin have a synergistic action that increases the solubility of DOMP and, perhaps, its bioavailability.